Mergers and acquisitions continue to be on big pharmaceutical companies agendas, page-3

And yet another biotech company is gobbled up. It's relentless

Who do you think has been sizing up Starpharma?

Clementia Pharmaceuticals (NASDAQ: CMTA) announced that it will be acquired by Ipsen (Euronext: IPN; ADR: IPSEY) for $25 per share in cash upfront or $1.04b, plus deferred payments on the achievement of a future regulatory milestone in the form of a contingent value right (CVR) of $6 per share upon FDA acceptance of the NDA filing for palovarotene for the treatment of Multiple Osteochondroma, representing an additional potential payment of $263m. Shares closed up 74% to $26.06.